AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25087079 — intervention group
Group type: COMPARATOR
Intervention: Both groups (ETs and NAs)
Number of subjects: 60
Study 25087079 — intervention group
Group type: COMPARATOR
Intervention: Indexed left ventricular end-diastolic volume
Number of subjects: 60
Study 21780182 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (0.8 mg folic acid, 0.5 mg vitamin B12, 20 mg vitamin B6)
Number of subjects: 266
Study 21780182 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins
Number of subjects: 266
Study 21780182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 19089502 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 3
Study 19089502 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 3
Study 17444926 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating carrots and resisting cookies (high self-regulatory effort)
Number of subjects: 0
Study 17444926 — intervention group
Group type: COMPARATOR
Intervention: Eating cookies and resisting carrots (low self-regulatory effort)
Number of subjects: 0
Study 17444926 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRV
Number of subjects: 0
Study 15189364 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 2631
Study 15189364 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 2631
Study 15189364 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes incidence
Number of subjects: 2631
Study 12358304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical instillation of non-selective beta-adrenoceptor antagonist (timolol)
Number of subjects: 0
Study 12358304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical instillation of selective beta-adrenoceptor antagonist (betaxolol)
Number of subjects: 0
Study 12358304 — intervention group
Group type: EXPERIMENTAL
Intervention: Short (10 s) and long (3 min) duration far (0D) and near (3D above tonic level) tasks
Number of subjects: 0
Study 9103279 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 17
Study 9103279 — intervention group
Group type: COMPARATOR
Intervention: Fruits and vegetables
Number of subjects: 17
Study 9103279 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of salicylates
Number of subjects: 17
Study 9103279 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with (acetyl)salicylic acid
Number of subjects: 17
Study 10148570 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 6
Study 10148570 — intervention group
Group type: COMPARATOR
Intervention: Non heparin-coated circuit with systemic heparin
Number of subjects: 6
Study 2423061 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 565
Study 2423061 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 565
Study 31876749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy alveolar lavage combined with thoracoscopy
Number of subjects: 174
Study 31876749 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopy (Control Group A)
Number of subjects: 174
Study 29124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge intervention
Number of subjects: 20
Study 29124826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity hygiene education (HE) intervention
Number of subjects: 20
Study 29124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous delivery of HE intervention
Number of subjects: 20
Study 29124826 — intervention group
Group type: COMPARATOR
Intervention: Sequential delivery of HE intervention
Number of subjects: 20
Study 29124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous nudge intervention delivery
Number of subjects: 20
Study 29124826 — intervention group
Group type: COMPARATOR
Intervention: Sequential nudge intervention delivery
Number of subjects: 20
Study 26863152 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week complex physical activity intervention
Number of subjects: 0
Study 26863152 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaches' perceptions of intervention fidelity
Number of subjects: 0
Study 26863152 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cost of developing the intervention and providing training
Number of subjects: 0
Study 24440236 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic tube drainage with early urethral catheter removal (removed on postoperative day 1)
Number of subjects: 58
Study 24440236 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheter drainage alone (catheter removed on postoperative day 7)
Number of subjects: 58
Study 24440236 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic tube drainage with early urethral catheter removal
Number of subjects: 58
Study 24440236 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheter drainage alone
Number of subjects: 58
Study 22505499 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 200
Study 22505499 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 200
Study 20456841 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative respiratory rehabilitation training (Group D)
Number of subjects: 80
Study 20456841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern rehabilitation training (Group C)
Number of subjects: 80
Study 20456841 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional qigong training (Group B)
Number of subjects: 80
Study 20456841 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (Group A)
Number of subjects: 80
Study 18588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction schedules for common allergenic foods
Number of subjects: 63
Study 18588557 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive challenges (37)
Number of subjects: 63
Study 16100296 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tablets mixed in 240 mL nutritional supplement drink followed by 120 mL water
Number of subjects: 32
Study 16100296 — intervention group
Group type: COMPARATOR
Intervention: Whole tablets swallowed with 240 mL water
Number of subjects: 32
Study 12413755 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 28
Study 12413755 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask
Number of subjects: 28
Study 10609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (participants were asked to chew at least one piece of gum and had free access to chewing gum throughout the experimental session)
Number of subjects: 20
Study 10609978 — intervention group
Group type: COMPARATOR
Intervention: No-gum control (participants did not chew gum)
Number of subjects: 20
Study 8935118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 13
Study 8935118 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac‐Fil
Number of subjects: 13
Study 8935118 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 13
Study 8935118 — intervention group
Group type: EXPERIMENTAL
Intervention: All materials
Number of subjects: 13
Study 1648432 — intervention group
Group type: EXPERIMENTAL
Intervention: RTOG Staging System
Number of subjects: 850
Study 1648432 — intervention group
Group type: EXPERIMENTAL
Intervention: RTOG Stage III (462 patients)
Number of subjects: 850
Study 1648432 — intervention group
Group type: EXPERIMENTAL
Intervention: AJCC Stage IIIA (348 patients)
Number of subjects: 850
Study 6360038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 77
Study 6360038 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-tobramycin
Number of subjects: 77
Study 31711528 — intervention group
Group type: COMPARATOR
Intervention: Standard doses (20 μg IM at months 0, 1, and 6); n=44
Number of subjects: 132
Study 31711528 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses (20 μg IM at months 0, 1, 2, 6); n=44
Number of subjects: 132
Study 31711528 — intervention group
Group type: EXPERIMENTAL
Intervention: Four double doses (40 μg IM at months 0, 1, 2, and 6); n=44
Number of subjects: 132
Study 29446267 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial mask with silicone chin cup
Number of subjects: 200
Study 29446267 — intervention group
Group type: COMPARATOR
Intervention: Facial mask without silicone chin cup
Number of subjects: 200
Study 26811090 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (300 mg/day for 10 days)
Number of subjects: 28
Study 26811090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24535415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) at dosages of 1.2, 2.4, and 4.8 g/day for 6 weeks
Number of subjects: 48
Study 24535415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) at high dosage (4.8 g/day)
Number of subjects: 48
Study 24535415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA)
Number of subjects: 48
Study 24535415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22277680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus arsenic trioxide (ATO)
Number of subjects: 22
Study 22277680 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 22
Study 20394254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 45 mg
Number of subjects: 72
Study 20394254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg
Number of subjects: 72
Study 20394254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 72
Study 17110451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation (150 mug daily for 6 months)
Number of subjects: 70
Study 17110451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16354361 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Number of subjects: 41
Study 12468788 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait trainer therapy (2 weeks)
Number of subjects: 30
Study 12468788 — intervention group
Group type: COMPARATOR
Intervention: Treadmill therapy (2 weeks)
Number of subjects: 30
Study 9672577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory training program for managers
Number of subjects: 94
Study 9672577 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary training program for managers
Number of subjects: 94
Study 9672577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 94
Study 8605522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (rBS/WC)
Number of subjects: 1165
Study 8605522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (killed Escherichia coli K12)
Number of subjects: 1165
Study 2686256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg/day) added to nitrates, beta-blockers, and calcium entry blockers
Number of subjects: 27
Study 2686256 — intervention group
Group type: COMPARATOR
Intervention: Nitrates, beta-blockers, and calcium entry blockers (without aspirin)
Number of subjects: 27
Study 4610853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment within the first 24 hours of thermal injuries
Number of subjects: 191
Study 4610853 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of burn
Number of subjects: 191
Study 31521046 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day shared decision making (SDM) program
Number of subjects: 88
Study 31521046 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 88
Study 28382877 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of CYP2R1 rs10500804, GC rs4588 and rs7041
Number of subjects: 642
Study 28382877 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles homozygosity of rs10741657 and rs1562902 in CYP2R1
Number of subjects: 642
Study 28382877 — intervention group
Group type: EXPERIMENTAL
Intervention: GC rs7041
Number of subjects: 642
Study 25773378 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg)
Number of subjects: 2341
Study 25773378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2341
Study 25773378 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 2341
Study 22090268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump delivery of PTH 1-34
Number of subjects: 8
Study 20370312 — intervention group
Group type: EXPERIMENTAL
Intervention: BIT (Behavioral Internet Treatment)
Number of subjects: 442
Study 20370312 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 442
Study 18358369 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (HXLPE)
Number of subjects: 54
Study 18358369 — intervention group
Group type: COMPARATOR
Intervention: Standard ultra-high-molecular-weight polyethylene (UHMWPE)
Number of subjects: 54
Study 18358369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both polyethylene types
Number of subjects: 54
Study 15999906 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (sedative and non-sedative neuroleptics, antidepressants, tranquilizers, hypnotics, psychostimulants, cognition-enhancing drugs)
Number of subjects: 0
Study 15999906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15999906 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 12113585 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA velocity (PSAV) in non-cancer subjects
Number of subjects: 1666
Study 12113585 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA velocity (PSAV) in cancer patients
Number of subjects: 1666
Study 12113585 — intervention group
Group type: COMPARATOR
Intervention: PSAV cutoff of 0.75 ng/mL/year
Number of subjects: 1666
Study 12113585 — intervention group
Group type: COMPARATOR
Intervention: PSAV cutoff of 0.10 ng/mL/year
Number of subjects: 1666
Study 10529071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 57
Study 10529071 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 57
Study 7747716 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy and mitomycin C
Number of subjects: 178
Study 7747716 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy alone
Number of subjects: 178
Study 2188479 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (up to 90 mg per day)
Number of subjects: 48
Study 2188479 — intervention group
Group type: COMPARATOR
Intervention: maprotiline (up to 150 mg per day)
Number of subjects: 48
Study 6117728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone‐marrow transplant from a matched allogeneic sibling
Number of subjects: 2
Study 6117728 — intervention group
Group type: COMPARATOR
Intervention: Drugs to induce initial remission
Number of subjects: 2
Study 31900198 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram or Nortriptyline
Number of subjects: 380
Study 30456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who took their children for eye tests
Number of subjects: 173
Study 30456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' acceptance of children wearing spectacles
Number of subjects: 173
Study 30456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' knowledge about child eye conditions
Number of subjects: 173
Study 30456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between family member wearing spectacles and child eye testing
Number of subjects: 173
Study 30456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between education level and knowledge of eye conditions
Number of subjects: 173
Study 30456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about eye health with family member wearing spectacles
Number of subjects: 173
Study 27502805 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment
Number of subjects: 120
Study 27502805 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific foot massage
Number of subjects: 120
Study 24817242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinotopic protocol consisting of twice-daily saline rinses, nebulized corticosteroid, and nebulized antibiotic for 6 weeks, followed by once-weekly endoscopic sinus debridement and topical intrasinus installation of corticosteroid and antibiotic.
Number of subjects: 20
Study 24817242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinotopic protocol
Number of subjects: 20
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 180 mg single-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 360 mg single-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 600 mg single-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 900 mg single-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 60 mg multiple-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 180 mg multiple-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 360 mg multiple-dose
Number of subjects: 180
Study 22284902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 (all doses)
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 (multiple doses)
Number of subjects: 180
Study 22284902 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 (360 mg repeated administration)
Number of subjects: 180
Study 21084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimanual massed practice (MP) training with somatosensory stimulation (SS)
Number of subjects: 13
Study 21084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual massed practice (MP) training with somatosensory stimulation (SS)
Number of subjects: 13
Study 21084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both unimanual and bimanual MP + SS
Number of subjects: 13
Study 18175733 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (34% of energy)
Number of subjects: 79
Study 18175733 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (64% of energy)
Number of subjects: 79
Study 18175733 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 79
Study 18175733 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 79
Study 15920044 — intervention group
Group type: EXPERIMENTAL
Intervention: C therapy (combination therapy weight loss program for 2 years)
Number of subjects: 59
Study 15920044 — intervention group
Group type: COMPARATOR
Intervention: S/C therapy (standard therapy weight loss program for 1 year followed by combination therapy in the 2nd year)
Number of subjects: 59
Study 13679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with biologically standardized mushroom extract at a maintenance dosage of 0.1 mg/ml of Alt a I
Number of subjects: 28
Study 13679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with biologically standardized mushroom extract
Number of subjects: 28
Study 10479145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonavalent pneumococcal conjugate vaccine
Number of subjects: 500
Study 10479145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 8983438 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 23
Study 8983438 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 23
Study 1774653 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical-zone-directed incisions
Number of subjects: 5
Study 1774653 — intervention group
Group type: COMPARATOR
Intervention: Limbus-directed incisions
Number of subjects: 5
Study 7075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 15
Study 7075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg
Number of subjects: 15
Study 7075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 15
Study 7075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg
Number of subjects: 15
Study 7075499 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 15
Study 7075499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31062540 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 1 (n=10) - 25-35 breaths at 55% maximal inspiratory pressure
Number of subjects: 30
Study 31062540 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 2 (n=10) - 45-55 breaths at 40% maximal inspiratory pressure
Number of subjects: 30
Study 31062540 — intervention group
Group type: COMPARATOR
Intervention: Sham-control group (n=10) - 30 breaths at 15% maximal inspiratory pressure
Number of subjects: 30
Study 29074892 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine for 14 days
Number of subjects: 0
Study 29074892 — intervention group
Group type: COMPARATOR
Intervention: No medication for 14 days (Control)
Number of subjects: 0
Study 26588111 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naproxen sodium 660 mg (single dose)
Number of subjects: 0
Study 26588111 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release naproxen sodium 220 mg tid
Number of subjects: 0
Study 26588111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23949016 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (HEMA-free one-step adhesive)
Number of subjects: 52
Study 23949016 — intervention group
Group type: COMPARATOR
Intervention: Optibond FL (three-step etch-and-rinse adhesive)
Number of subjects: 52
Study 23949016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adhesives
Number of subjects: 52
Study 21726428 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 46
Study 21726428 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 46